$199.05
-0.57(-0.29%)
Mkt Cap $4.0B
$96.67
$221.24
52-Week Range
At A Glance
1
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.
2
Revenue is primarily driven by Royalty (21.5%) and Intangible Royalty Assets (18.9%).
3
Most recently: Results of Operations and Financial Condition. On February 26. 2026, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its f (2026-02-26).
$4.0B
Market Cap
$271M
Revenue
$126M
Net Income
Employees68
Fundamentals
How The Business Makes Money
Revenue by Segment
Royalty21.5%($355M)
Intangible Royalty Assets18.9%($312M)
Contract Revenue And Income10%($165M)
Contract Revenue6.8%($112M)
Royalty Kyprolis6.6%($110M)
Material Sales Captisol6%($99M)
Material Sales Captisol Core6%($99M)
Income From Divestiture Transactions3.2%($53M)
Service3%($50M)
Filspari2.8%($47M)
Financial Royalty Assets2.6%($43M)
Royalty Rylaze2.5%($41M)
QARZIBA2.1%($35M)
Royalty Teriparatide Injection1.7%($27M)
Royalty Evomela1.5%($25M)
Royalty Other1.5%($25M)
Vaxneuvance1%($17M)
Capvaxive0.6%($11M)
Ohtuvayre0.6%($11M)
License Fees0.5%($9M)
Financial Royalty Other0.5%($8M)
Activity
Analyst View
Company Profile
CIK0000886163
ISINUS53220K5048
CUSIP53220K504
Phone858 550 7500
Address5980 Horton Street, Jupiter, CA, 94608, US
SEC EDGAR